Nurix Therapeutics(NRIX) - 2024 Q4 - Annual Results

[Nurix Logo] Exhibit 99.1 Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases Advance our portfolio of partnered programs in inflammation and immunology, including degraders of IRAK4 and STAT6 Invest in our highly productive DEL-AI discovery engine to create and advance novel degrader-based treatments in our wholly owned and partnered portfolios Maintain a strong financial position, building on our estimated $609.6 million in cash an ...